{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T03:08:50Z","timestamp":1774494530169,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T00:00:00Z","timestamp":1463443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T00:00:00Z","timestamp":1463443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1038\/pcan.2016.16","type":"journal-article","created":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T10:22:03Z","timestamp":1463480523000},"page":"283-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance"],"prefix":"10.1038","volume":"19","author":[{"given":"J P","family":"Radtke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T H","family":"Kuru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Bonekamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M T","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M B","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C D","family":"Alt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Hatiboglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Boxler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Pahernik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M C","family":"Roethke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H P","family":"Schlemmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Hohenfellner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B A","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,17]]},"reference":[{"key":"BFpcan201616_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.eururo.2012.08.001","volume":"63","author":"JR Rider","year":"2013","unstructured":"Rider JR, Sandin F, Andr\u00e9n O, Wiklund P, Hugosson J, Stattin P . Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol 2013; 63: 88\u201396.","journal-title":"Eur Urol"},{"key":"BFpcan201616_CR2","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0022-5347(05)65174-9","volume":"167","author":"R Choo","year":"2002","unstructured":"Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and\/or clinical progression. J Urol 2002; 167: 1664\u20131669.","journal-title":"J Urol"},{"key":"BFpcan201616_CR3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","volume":"33","author":"L Klotz","year":"2014","unstructured":"Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2014; 33: 272\u2013277.","journal-title":"J Clin Oncol"},{"key":"BFpcan201616_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.eururo.2011.05.006","volume":"60","author":"G Ploussard","year":"2011","unstructured":"Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm M-O et al. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 2011; 60: 291\u2013303.","journal-title":"Eur Urol"},{"key":"BFpcan201616_CR5","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/bjc.2014.192","volume":"110","author":"GL Shaw","year":"2014","unstructured":"Shaw GL, Thomas BC, Dawson SN, Srivastava G, Vowler SL, Gnanapragasam VJ et al. Identification of pathologically insignificant prostate cancer is not accurate in unscreened men. Br J Cancer 2014; 110: 2405\u20132411.","journal-title":"Br J Cancer"},{"key":"BFpcan201616_CR6","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.juro.2011.07.013","volume":"186","author":"B Turkbey","year":"2011","unstructured":"Turkbey B, Mani H, Shah V, Rastinehad AR, Bernardo M, Pohida T et al. Multiparametric 3 T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol 2011; 186: 1818\u20131824.","journal-title":"J Urol"},{"key":"BFpcan201616_CR7","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.eururo.2013.03.030","volume":"64","author":"CM Moore","year":"2013","unstructured":"Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Futterer JJ, Gill IS et al. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol 2013; 64: 544\u2013552.","journal-title":"Eur Urol"},{"key":"BFpcan201616_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2214\/AJR.13.11046","volume":"202","author":"M De Rooij","year":"2014","unstructured":"De Rooij M, Hamoen EHJ, F\u00fctterer JJ, Barentsz JO, Rovers MM . Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. Am J Roentgenol 2014; 202: 343\u2013351.","journal-title":"Am J Roentgenol"},{"key":"BFpcan201616_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1148\/radiol.09090475","volume":"255","author":"B Turkbey","year":"2010","unstructured":"Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection\u2013histopathologic correlation. Radiology 2010; 255: 89\u201399.","journal-title":"Radiology"},{"key":"BFpcan201616_CR10","doi-asserted-by":"publisher","first-page":"830","DOI":"10.2214\/AJR.11.8446","volume":"199","author":"AB Rosenkrantz","year":"2012","unstructured":"Rosenkrantz AB, Deng FM, Kim S, Lim RP, Hindman N, Mussi TC et al. Prostate cancer: multiparametric MRI for index lesion localization\u2014a multiple-reader study. Am J Roentgenol 2012; 199: 830\u2013837.","journal-title":"Am J Roentgenol"},{"key":"BFpcan201616_CR11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.eururo.2014.08.079","volume":"67","author":"JD Le","year":"2014","unstructured":"Le JD, Tan N, Shkolyar E, Lu DY, Kwan L, Marks LS et al. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol 2014; 67: 569\u2013576.","journal-title":"Eur Urol"},{"key":"BFpcan201616_CR12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.eururo.2014.08.077","volume":"67","author":"E Baco","year":"2014","unstructured":"Baco E, Ukimura O, Rud E, Vlatkovic L, Svindland A, Aron M et al. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol 2014; 67: 787\u2013794.","journal-title":"Eur Urol"},{"key":"BFpcan201616_CR13","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.juro.2014.11.002","volume":"193","author":"NB Delongchamps","year":"2014","unstructured":"Delongchamps NB, Lef\u00e8vre A, Bouazza N, Beuvon F, Legman P, Cornud F . Detection of significant prostate cancer with magnetic resonance targeted biopsies\u2014should transrectal ultrasound-magnetic resonance imaging fusion guided biopsies alone be a standard of care? J Urol 2014; 193: 1198\u20131204.","journal-title":"J Urol"},{"key":"BFpcan201616_CR14","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/j.juro.2012.07.024","volume":"188","author":"HA Vargas","year":"2012","unstructured":"Vargas HA, Akin O, Afaq A, Goldman D, Zheng J, Moskowitz CS et al. Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol 2012; 188: 1732\u20131738.","journal-title":"J Urol"},{"key":"BFpcan201616_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.juro.2014.02.005","volume":"192","author":"JC Hu","year":"2014","unstructured":"Hu JC, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P et al. Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply? J Urol 2014; 192: 385\u2013390.","journal-title":"J Urol"},{"key":"BFpcan201616_CR16","first-page":"67","volume":"67","author":"IG Schoots","year":"2014","unstructured":"Schoots IG, Petrides N, Giganti F, Bokhorst LP, Rannikko A, Klotz L et al. Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. Eur Urol 2014; 67: 67\u201373.","journal-title":"Eur Urol"},{"key":"BFpcan201616_CR17","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.eururo.2007.05.011","volume":"52","author":"RCN Van den Bergh","year":"2007","unstructured":"Van den Bergh RCN, Roemeling S, Roobol MJ, Roobol W, Schr\u00f6der FH, Bangma CH . Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 2007; 52: 1560\u20131563.","journal-title":"Eur Urol"},{"key":"BFpcan201616_CR18","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1002\/cncr.28216","volume":"119","author":"L Stamatakis","year":"2013","unstructured":"Stamatakis L, Siddiqui MM, Nix JW, Logan J, Rais-Bahrami S, Walton-Diaz A et al. Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer 2013; 119: 3359\u20133366.","journal-title":"Cancer"},{"key":"BFpcan201616_CR19","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.juro.2015.01.088","volume":"193","author":"MM Siddiqui","year":"2015","unstructured":"Siddiqui MM, Truong H, Rais-Bahrami S, Stamatakis L, Logan J, Walton-Diaz A et al. Clinical implications of a multiparametric MRI based nomogram applied to prostate cancer active surveillance. J Urol 2015; 193: 1943\u20131949.","journal-title":"J Urol"},{"key":"BFpcan201616_CR20","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.juro.2013.04.043","volume":"190","author":"TH Kuru","year":"2013","unstructured":"Kuru TH, Roethke MC, Seidenader J, Simpfendorfer T, Boxler S, Alammar K et al. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer. J Urol 2013; 190: 1380\u20131386.","journal-title":"J Urol"},{"key":"BFpcan201616_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.juro.2014.07.098","volume":"193","author":"JP Radtke","year":"2015","unstructured":"Radtke JP, Kuru TH, Boxler S, Alt CD, Popeneciu IV, Huettenbrink C et al. Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance. J Urol 2015; 193: 87\u201394.","journal-title":"J Urol"},{"issue":"4","key":"BFpcan201616_CR22","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s00330-011-2377-y","volume":"22","author":"Jelle O. Barentsz","year":"2012","unstructured":"Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012 22: 746\u2013757.","journal-title":"European Radiology"},{"key":"BFpcan201616_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/modpathol.2010.156","volume":"24","author":"TH Van der Kwast","year":"2011","unstructured":"Van der Kwast TH, Amin MB, Billis A, Epstein JI, Griffiths DF, Humphrey PA et al. International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. working group 1: specimen handling. Mod Pathol 2011; 24: 16\u201325.","journal-title":"Mod Pathol"},{"key":"BFpcan201616_CR24","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<891::AID-SIM780>3.0.CO;2-B","volume":"17","author":"T Tango","year":"1998","unstructured":"Tango T . Equivalence test and confidence interval for the difference in proportions for the paired-sample design. Stat Med 1998; 17: 891\u2013908.","journal-title":"Stat Med"},{"key":"BFpcan201616_CR25","first-page":"409","volume":"1","author":"R Development Core Team R","year":"2014","unstructured":"R Development Core Team R. R: a language and environment for statistical computing. R Found Stat Comput 2014; 1: 409.","journal-title":"R Found Stat Comput"},{"key":"BFpcan201616_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1148\/radiol.2261021292","volume":"226","author":"PM Bossuyt","year":"2003","unstructured":"Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis Ca, Glasziou PP, Irwig LM et al. Towards complete and,accurate reporting of studies of diagnostic accuracy: the STARD initiative. Radiology 2003; 226: 24\u201328.","journal-title":"Radiology"},{"key":"BFpcan201616_CR27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.juro.2015.02.2938","volume":"194","author":"A Ouzzane","year":"2015","unstructured":"Ouzzane A, Renard-Penna R, Marliere F, Mozer P, Olivier J, Barkatz J et al. MRI-targeted biopsy improves selection of patients considered for active surveillance for clinically low-risk prostate cancer based on systematic biopsies. J Urol 2015; 194: 350\u2013356.","journal-title":"J Urol"},{"key":"BFpcan201616_CR28","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.juro.2012.04.107","volume":"188","author":"WE Barzell","year":"2012","unstructured":"Barzell WE, Melamed MR, Cathcart P, Moore CM, Ahmed HU, Emberton M . Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer. J Urol 2012; 188: 762\u2013767.","journal-title":"J Urol"},{"key":"BFpcan201616_CR29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1148\/radiol.13121325","volume":"268","author":"B Turkbey","year":"2013","unstructured":"Turkbey B, Mani H, Aras O, Ho J, Hoang A, Rastinehad AR et al. Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology 2013; 268: 144\u2013152.","journal-title":"Radiology"},{"key":"BFpcan201616_CR30","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.urology.2014.02.070","volume":"84","author":"L Villa","year":"2014","unstructured":"Villa L, Salonia A, Capitanio U, Scattoni V, Abdollah F, Suardi N et al. The Number of cores at first biopsy may suggest the need for a con fi rmatory decision making in the real-life setting. Urology 2014; 84: 634\u2013641.","journal-title":"Urology"},{"key":"BFpcan201616_CR31","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.eururo.2009.07.053","volume":"56","author":"G Ploussard","year":"2009","unstructured":"Ploussard G, Xylinas E, Salomon L, Allory Y, Vordos D, Hoznek A et al. The role of biopsy core number in selecting prostate cancer patients for active surveillance. Eur Urol 2009; 56: 891\u2013898.","journal-title":"Eur Urol"},{"key":"BFpcan201616_CR32","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/j.1464-410X.2012.11641.x","volume":"111","author":"JK Mullins","year":"2013","unstructured":"Mullins JK, Bonekamp D, Landis P, Begum H, Partin AW, Epstein JI et al. Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. BJU Int 2013; 111: 1037\u20131045.","journal-title":"BJU Int"},{"key":"BFpcan201616_CR33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.urology.2014.06.085","volume":"85","author":"SS Dianat","year":"2015","unstructured":"Dianat SS, Carter HB, Pienta KJ, Schaeffer EM, Landis PK, Epstein JI et al. Magnetic resonance e invisible versus magnetic resonance e visible prostate cancer in active surveillance: a preliminary report on disease outcomes. Urology 2015; 85: 147\u2013154.","journal-title":"Urology"},{"key":"BFpcan201616_CR34","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/bju.12423","volume":"113","author":"BH Park","year":"2014","unstructured":"Park BH, Jeon HG, Choo SH, Jeong BC, Seo SI, Jeon SS et al. Role of multiparametric 3.0-Tesla magnetic resonance imaging in patients with prostate cancer eligible for active surveillance. BJU Int 2014; 113: 864\u2013870.","journal-title":"BJU Int"},{"key":"BFpcan201616_CR35","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/jmri.24710","volume":"41","author":"MR Da Rosa","year":"2015","unstructured":"Da Rosa MR, Milot L, Sugar L, Vesprini D, Chung H, Loblaw A et al. A prospective comparison of MRI-US fused targeted biopsy versus systematic ultrasound-guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance. J Magn Reson Imaging 2015; 41: 220\u2013225.","journal-title":"J Magn Reson Imaging"},{"key":"BFpcan201616_CR36","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.eururo.2014.08.077","volume":"67","author":"E Baco","year":"2015","unstructured":"Baco E, Ukimura O, Rud E, Vlatkovic L, Svindland A, Aron M et al. Magnetic resonance imaging\u2013transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol 2015; 67: 787\u2013794.","journal-title":"Eur Urol"},{"key":"BFpcan201616_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.juro.2014.01.014","volume":"192","author":"JE Thompson","year":"2014","unstructured":"Thompson JE, Moses D, Shnier R, Brenner P, Delprado W, Ponsky L et al. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. J Urol 2014; 192: 67\u201374.","journal-title":"J Urol"},{"key":"BFpcan201616_CR38","doi-asserted-by":"publisher","first-page":"202.e1","DOI":"10.1016\/j.urolonc.2015.01.023","volume":"33","author":"A Walton Diaz","year":"2015","unstructured":"Walton Diaz A, Shakir NA, George AK, Rais-Bahrami S, Turkbey B, Rothwax JT et al. Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance. Urol Oncol Semin Orig Investig 2015; 33: 202.e1\u2013202.e7.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"BFpcan201616_CR39","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.eururo.2014.11.037","volume":"68","author":"IG Schoots","year":"2014","unstructured":"Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MGM . Magnetic resonance imaging\u2013targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol 2014; 68: 438\u2013450.","journal-title":"Eur Urol"},{"key":"BFpcan201616_CR40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/pcan.2015.20","volume":"18","author":"R Guo","year":"2015","unstructured":"Guo R, Cai L, Fan Y, Jin J, Zhou L, Zhang K . Magnetic resonance imaging on disease reclassification among active surveillance candidates with low-risk prostate cancer: a diagnostic meta-analysis. Prostate Cancer Prostatic Dis 2015; 18: 221\u2013228.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFpcan201616_CR41","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.eururo.2013.08.060","volume":"66","author":"KC Cary","year":"2014","unstructured":"Cary KC, Cowan JE, Sanford M, Shinohara K, Perez N, Chan JM et al. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies. Eur Urol 2014; 66: 337\u2013342.","journal-title":"Eur Urol"},{"key":"BFpcan201616_CR42","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.juro.2015.02.015","volume":"194","author":"KT Dinh","year":"2015","unstructured":"Dinh KT, Mahal Ba, Ziehr DR, Muralidhar V, Chen Y-W, Viswanathan VB et al. Incidence and predictors of upgrading and upstaging among 10,000 contemporary patients with low-risk prostate cancer. J Urol 2015; 194: 343\u2013349.","journal-title":"J Urol"},{"key":"BFpcan201616_CR43","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.juro.2015.06.084","volume":"194","author":"CB Anderson","year":"2015","unstructured":"Anderson CB, Sternberg IA, Karen-Paz G, Kim PH, Sjoberg D, Vargas HA et al. Age is associated with upgrading at confirmatory biopsy among men with prostate cancer treated with active surveillance. J Urol 2015; 194: 1607\u20131611.","journal-title":"J Urol"},{"key":"BFpcan201616_CR44","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/cncr.26234","volume":"118","author":"N Suardi","year":"2012","unstructured":"Suardi N, Gallina A, Capitanio U, Salonia A, Lughezzani G, Freschi M et al. Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients. Cancer 2012; 118: 973\u2013980.","journal-title":"Cancer"},{"key":"BFpcan201616_CR45","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/ncpuro1131","volume":"5","author":"L Klotz","year":"2008","unstructured":"Klotz L . Nomogram for predicting survival in men with clinically localized prostate cancer who do not undergo definitive therapy. Nat Clin Pract Urol 2008; 5: 362\u2013363.","journal-title":"Nat Clin Pract Urol"},{"key":"BFpcan201616_CR46","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.eururo.2015.03.023","volume":"68","author":"DP Ankerst","year":"2015","unstructured":"Ankerst DP, Xia J, Thompson IM, Hoefler J, Newcomb LF, Brooks JD et al. Precision medicine in active surveillance for prostate cancer: development of the canary\u2013early detection research network active surveillance biopsy risk calculator. Eur Urol 2015; 68: 1083\u20131088.","journal-title":"Eur Urol"},{"key":"BFpcan201616_CR47","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1016\/j.juro.2007.08.039","volume":"178","author":"HB Carter","year":"2007","unstructured":"Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007; 178: 2359\u20132365.","journal-title":"J Urol"},{"key":"BFpcan201616_CR48","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.juro.2015.04.109","volume":"194","author":"KN Pham","year":"2015","unstructured":"Pham KN, Porter CR, Odem-Davis K, Wolff EM, Jeldres C, Wei JT et al. Transperineal template guided prostate biopsy selects candidates for active surveillance\u2014how many cores are enough? J Urol 2015; 194: 674\u2013679.","journal-title":"J Urol"},{"key":"BFpcan201616_CR49","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1016\/j.juro.2013.05.015","volume":"190","author":"AC Reese","year":"2013","unstructured":"Reese AC, Landis P, Han M, Epstein JI, Carter HB . Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis. J Urol 2013; 190: 2033\u20132038.","journal-title":"J Urol"},{"key":"BFpcan201616_CR50","doi-asserted-by":"publisher","first-page":"71.e1","DOI":"10.1016\/j.urolonc.2014.07.007","volume":"33","author":"G Ploussard","year":"2015","unstructured":"Ploussard G, Isbarn H, Briganti A, Sooriakumaran P, Surcel CI, Salomon L et al. Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients. Urol Oncol Semin Orig Investig 2015; 33: 71.e1\u201371.e9.","journal-title":"Urol Oncol Semin Orig Investig"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/pcan201616.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201616","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201616.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:08:12Z","timestamp":1648674492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan201616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,17]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["BFpcan201616"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2016.16","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,17]]},"assertion":[{"value":"18 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BAH has received research funding from MedCom and Uromed. The remaining authors declare on conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}